利培酮合用米氮平治疗精神分裂症阴性症状的研究

目的　探讨米氮平治疗精神分裂症阴性症状的疗效和安全性。方法　将 86例以阴性症状为主的住院精神分裂症患者随机分为研究组对对照组 ,分别给予利培酮合用米氮平及单用利培酮治疗 ,疗程 12周 ,用PANSS、TESS评定疗效和安全性。结果　疗后 4周两组PANSS总分、阳性因子分、阴性因子分及 8、12周末两组PANSS总分和各因子分与疗前比较差异有显著性 (P <0 0 5或P <0 0 1)。治疗后 8、12周两组间比较PANSS总分及阴性因子分差异有显著性 (P <0 0 5或P <0 0 1)。结论　米氮平治疗精神分裂症阴性症状疗效较好 ,副作用少。

Control study of risperidone and mirtazapine on negative symptoms of schizophrenia

Objective: To study the efficacy and safty of mirtazapine on negative symptoms of schizophrenia. Methods: 86 cases of schizophrenia with promient negative symptoms were randomly enrolled into study group (n=43) and control group (n=43). 43 cases of risperidone and mirtazapine treated patients were compared with 43 cases of risperidone only treated patients. The duration of study was 12 weeks. The PANSS and TESS were enployed for assessing the therapeutic efficacy and safty respectively. Results: After treatment, the total scores of PANSS and TESS were significantly different between two groups (P<0.05 or P<0.01), especially the total scores of PANSS were significantly different after 8 weeks of study between two groups (P<0.05 or P<0.01), but the total scores of TESS had no significantly different (P>0.05). Conclusion: Mirtazapine had an excellent clinical efficacy and safty in the treatment of schizophrenics with prominent negative symptoms.